In cell and gene therapy, manufacturing partnerships are often the difference between promising science and clinical reality. A new agreement between OrganaBio LLC and RxMP Therapeutics highlights how early-stage companies are de-risking development by locking in specialized manufacturing expertise.
Under the deal, OrganaBio will serve as the contract manufacturing partner for RMP-402, RxMP’s lead haemostatic therapy candidate, supporting its progression toward clinical development.
Uncontrolled bleeding remains one of the leading causes of preventable death globally—particularly in trauma and surgical settings. Despite advances in emergency medicine, current interventions often:
RMP-402 is being developed to change that equation. This collaboration focuses on building the manufacturing backbone needed to move the therapy through critical development milestones—without delays that typically derail preclinical programs.
RMP-402 is a first-in-class haemostatic therapeutic designed for rapid control of severe bleeding.
The therapy targets a global trauma and surgical bleeding market estimated at $12 billion annually—an area with significant unmet medical need.
Under the agreement, OrganaBio will provide end-to-end cGMP manufacturing support.
The company will leverage its vertically integrated infrastructure—combining upstream sourcing of blood-derived materials with downstream manufacturing under a unified quality system. This integrated model is particularly relevant for biologically complex therapies like RMP-402.
The partnership comes at a pivotal stage for RxMP. Key developments already in place:
Next steps include:
By securing a manufacturing partner now, RxMP reduces execution risk at a stage where many therapies stall.
RMP-402 is not a conventional drug. It sits at the intersection of biologics, blood products, and advanced therapies. That creates unique manufacturing demands:
OrganaBio’s vertically integrated model—spanning sourcing, processing, and manufacturing—directly addresses these challenges.
One of the most strategic aspects of RMP-402 is its dual-use potential.
The involvement of the Department of Defense signals strong interest in battlefield applications, where rapid bleeding control can be the difference between life and death.
This deal reinforces a broader trend in advanced therapeutics:
For companies like RxMP, choosing the right manufacturing partner is not operational—it is strategic.
The OrganaBio–RxMP partnership is a classic example of execution-first biotech strategy.
For RxMP, it delivers:
For OrganaBio, it reinforces:
For the broader industry, the takeaway is clear: Breakthrough therapies do not fail because of weak science. They fail because they cannot be manufactured reliably.